EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis

Xinlin Huang, Mi Zhang, Sheng Wang, Xue Wang iD

Journal of Cutaneous Medicine and Surgery · 2025

DOI: 10.1177/12034754251404468 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Medicine and Surgery, 2025. Verfasst von Xinlin Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate efficacy and safety of abrocitinib and dupilumab in the treatment of moderate-to-severe atopic dermatitis (AD).

Methods

A retrospective analysis of 104 patients with moderate-to-severe AD (January-June 2023) was conducted. Patients received either oral abrocitinib 200 mg/day (n = 51) or subcutaneous dupilumab 300 mg every 2 weeks (n = 53, baseline load 600 mg) for 24 weeks.

Results

At 4, 8, and 12 weeks posttreatment, patients in the abrocitinib group exhibited significantly lower Eczema Area and Severity Index (EASI) scores compared to the dupilumab group ( P < .05). Additionally, patients in the abrocitinib group demonstrated significantly lower Numeric Rating Scale for Pruritus (P-NRS) scores at 4, 8, 12, 16, and 24 weeks posttreatment compared to the dupilumab group ( P < .05). Furthermore, patients in the abrocitinib group showed significantly lower Dermatology Life Quality Index (DLQI) scores at 4, 8, 12, and 16 weeks posttreatment compared to the dupilumab group ( P < .05). Compared with dupilumab group, EASI, P-NRS and DLQI levels in abrocitinib group were more significantly decreased. The incidence of conjunctivitis in dupilumab group was significantly higher than that in abrocitinib group ( P < .05). The incidence of nausea in abrocitinib group was significantly higher than that in dupilumab group ( P < .05).

Conclusion

Both abrocitinib and dupilumab can significantly relieve pruritus and improve quality of life in patients with moderate-to-severe AD at 24 weeks after treatment, but abrocitinib is more effective in relieving pruritus. Both abrocitinib and dupilumab have high safety, but require attention for gastrointestinal symptoms and conjunctivitis, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansFemaleMaleRetrospective StudiesAdultSeverity of Illness IndexMiddle AgedTreatment OutcomePruritusInjections, SubcutaneousYoung AdultQuality of LifePyrimidinesSulfonamides

Stichwörter der Autor:innen

abrocitinibadultsatopic dermatitisdupilumabretrospective study

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedabrocitinibDermatologic AgentsPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Dermatology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
  • Department of Pharmacy, The First Affiliated Hospital of Shihezi University, Shihezi, China.

ORCID-Profile: Xue Wang

Zitieren

APA

Huang, X., Zhang, M., Wang, S., & Wang, X. (2025). Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754251404468

Vancouver

Huang X, Zhang M, Wang S, Wang X. Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery. 2025. doi:10.1177/12034754251404468

BibTeX
@article{Huang2025,
  author = {Huang, Xinlin and Zhang, Mi and Wang, Sheng and Wang, Xue},
  title = {Efficacy and Safety of Abrocitinib and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis},
  journal = {Journal of Cutaneous Medicine and Surgery},
  year = {2025},
  doi = {10.1177/12034754251404468}
}
Kostenlos starten →